Table 1 Baseline characteristics
From: Gene expression of fibrinolytic markers in coronary thrombi
Female sex | 3 (9%) |
Age (yrs) | 58.0 (54.0, 68.0) |
Current smokers | 16 (49%) |
Previous smokers | 11 (33%) |
BMI (kg/m2) | 27.7 (23.4, 28.6) |
Hypertension | 11 (33%) |
T2DM | 4 (12%) |
Previous coronary disease | 1 (3%) |
Medication before index MI: | |
ASA | 6 (18%) |
Clopidogrel/Prasugrel/Ticagrelor | 2 (6%) |
Warfarin | 1 (3%) |
NOAC | 2 (6%) |
Betablocker | 4 (12%) |
ACE-I | 0 (0%) |
AT-II-blocker | 5 (15%) |
Statins | 6 (18%) |
Diuretics | 4 (12%) |
Aldosterone antagonists | 0 (0%) |
Systolic BP (mmHg) | 126.0 (109.0, 144.0) |
Diastolic BP (mmHg) | 80.0 (70.0, 99.5) |
HR (beats/min) | 70.0 (65.0, 90) |
Ischemic time (min) | 152 (122, 343) |
CRP (mg/L) | 2.71 (1.00, 5.57) |
Troponin T after PCI (ng/L) | 354 (123, 744) |
Troponin T peak (ng/L) | 3434 (1250, 6967) |
Culpruit lesion: | |
LAD | 16 (49%) |
CX | 6 (18%) |
RCA | 11 (33%) |
Retrograde flow | 12 (36%) |
Three-vessel disease | 6 (18%) |
In-stent thrombus | 1 (3%) |